The FDA will allow Prolor Biotech to conduct a midstage study of a longer-acting formulation of its hGH-CTP human growth hormone. The Israeli company plans to test the version as a once-weekly or bimonthly treatment.
Published in Brief:
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.